Background-Mesenchymal stem cells (MSCs) can differentiate into endothelial cells in vivo. However, it is unknown if the differentiated MSCs persist in vivo and if this potential persistence contributes to functional improvement after experimental myocardial infarction. Methods and Results-We generated a lentivector encoding 2 distinct reporter genes, one driven by a constitutive murine stem cell virus promoter and the other driven by an endothelial-specific Tie-2 promoter. The endothelial specificity of the lentivector was validated by its expression in endothelial cells but not in human MSCs (hMSCs). The lentivirus-transduced hMSCs were injected into peri-infarct areas of the hearts of severe combined immune-deficient mice. Persistence of injected cells was tracked by bioluminescence imaging (BLI) and verified by immunohistochemical staining. The BLI signal from the endothelial-specific reporter revealed that hMSCs differentiated into endothelial cells 48 hours after injection. However, both the constitutive and endothelial-specific BLI signals disappeared by day 50. Nonetheless, the improvement in left ventricle ejection fraction with hMSC therapy persisted for up to 6 months. Immunohistochemical staining showed that hMSC-derived endothelial cells integrated into endogenous CD31 ϩ vessels. Furthermore, hMSC-transplanted hearts had more CD31 ϩ vessels and a lesser degree of cardiac fibrosis compared with the controls at 6 months. Conclusions-hMSCs differentiated into endothelial cells and integrated into blood vessels after experimental myocardial infarction. The differentiated hMSCs only lasted for up to 50 days in vivo, but improvement in cardiac function persisted for up to 6 months. Increased angiogenesis and decreased fibrosis were associated with cardiac functional improvement after hMSC transplantation. (Circ Cardiovasc Imaging. 2012;5:94-101.)
S
tem cell therapy for cardiovascular disease has been studied for over a decade. [1] [2] [3] Preclinical studies have demonstrated that the mesenchymal stem cells (MSCs) facilitate both myocardial repair and neovascularization in animal models of cardiac injury. 4 -7 Human clinical trials have also validated the safety and efficacy of MSC therapy in patients with acute myocardial infarction (MI) and heart failure. 8 -12 Endothelial cell differentiation and the paracrine effect have been proposed to be responsible for the efficacy of MSC therapy. However, it is not known if differentiated MSCs persist in vivo and if this potential persistence contributes to functional improvement after experimental MI (EMI). To determine the long-term fate of transplanted MSCs in vivo by imaging, we generated a lentivector encoding 2 distinct double-fusion reporter genes (DFRs). One DFR, GFP/fireflyluciferase (G/f-Luc), is controlled by an endothelial-specific promoter Tie-2, 13 and the other DFR, mCherry/renilla luciferase (C/r-Luc), is driven by the constitutively active U3 region from the murine stem cell virus-long terminal repeat. This lentivector is designed to track the long-term survival and proliferation of the injected human MSCs (hMSCs) in the infarcted hearts and to determine whether hMSCs undergo endothelial differentiation and, if so, the kinetics of such differentiation. Combined bioluminescence imaging (BLI), fluorescent imaging, and cardiac magnetic resonance imaging (MRI) demonstrated that injected hMSCs differentiate into endothelial cells in the injured hearts. However, the injected hMSCs persisted for only a limited time, suggesting that the long-term functional improvement after EMI is the result of paracrine effects.
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Methods Endothelial Cell-Specific Vector Construction and Lentiviral Packaging
The Tie-2 promoter was used to drive the expression of the G/f-Luc to facilitate endothelial cell-specific imaging. We first generated a bidirectional lentiviral dual-expression vector, pLVD430-C/r-Luc-G/ f-Luc, in which the constitutive expression of C/r-Luc and G/f-Luc DFR is controlled by the murine stem cell virus and human phosphoglycerate kinase promoters, respectively. We then modified the vector by replacing human phosphoglycerate kinase with the Tie-2 promoter. Briefly, the Tie-2 promoter was amplified by PCR from T2HpGFPT2I5/XK (kindly provided by Thomas N. Sato, PhD, Weill Medical College of Cornell University, New York) using primers designed to bind the regions flanking the promoter and containing BstB1 and ScaI restriction sites (italicized), respectively: forward, 5Ј-TAATTTCGAATCACACAGGAAACAGCTATGAC-3Ј; reverse, 5Ј-TAATAGTACTCGACGTTGTAAAACGACGGCCAGTG-3Ј. The final expression vector was produced by removing the phosphoglycerate kinase promoter via digestion of pLVD430-C/r-Luc-G/f-Luc with HpaI and BstBI and replacing it with the Tie-2 promoter, a 2-kb ScaI/BstBI-digested PCR product.
Lentiviral packaging, concentrating, and titering were performed as previously described. 14, 15 
Cell Culture and Lentiviral Transduction
The hMSCs (Lonza; Walkersville, MD) were cultured in supplemented MSCGM medium, according to manufacturer's specifications. Mouse cardiac endothelial cells (mETCs, Cedarlane; Burlington, NC) were cultured in DMEM supplemented with 10% serum at 30°C. The hMSCs and mETCs (at passages 3-6) were transduced with concentrated lentivirus at a multiplicity of infection of 30. The transduction efficiencies were assessed by measuring constitutive mCherry expression in hMSCs. Tie-2 endothelial-specific expression in the mETCs was validated by measuring GPF expression via fluorescent microscopy (FM) and flow cytometry (fluorescence-activated cell sorter [FACS] , BLR-II, BD Biosciences; San Jose, CA). Constitutive expression versus endothelial-specific expression was determined by measuring the BLI intensity of r-Luc and f-Luc with a Xenogen IVIS 200 system (Caliper LS), as previously described. 16, 17 The ratio of BLI signal/cell number was determined by plating serially diluted cells (1ϫ10 3 -1ϫ10 5 cells) in a 24-well plate and quantifying signal intensities in each well. The data were expressed as photons/s per cell.
Induction of MI, Injection of hMSCs, In Vivo BLI Tracking of Injected hMSCs, and Cardiac Functional Assessment
All animal studies were approved by the Institutional Animal Care and Use Committees of the University of Texas M. D. Anderson Cancer Center. Female severe combined immune-deficient (SCID) mice (C3H; weight, 16 -20 g; Jackson Laboratory; Bar Harbor, ME) were used in all in vivo studies. MI was induced as previously described. 18 After MI induction, 5ϫ10 5 lentivirus-transduced hMSCs were injected in 25 to 30 L of basal medium directly into the peri-infarcted areas of each heart. Control mice were injected with basal medium only. Each group consisted of 10 mice.
In vivo BLI was longitudinally performed using the same Xenogen IVIS system at different time points. Five minutes before imaging, each mouse received, via tail vein, 100 L of 40 mg/mL coelenterazine for detection of the constitutive BLI/r-Luc signal, indicating the total injected hMSC population, or a 100-L intraperitoneal injection of 125 mg/kg D-luciferin for assessment of the inducible BLI/f-Luc signal, indicating endothelial differentiation of injected hMSCs. 16, 17 To circumvent interference between BLI/r-Luc and BLI/f-Luc signals, the measurements were recorded 6 hours apart.
To assess cardiac function, a 7.0-T Biospec small animal scanner (Bruker Biospin Inc; Billerica, MA) was used to scan the mice longitudinally before (baseline) and after (week 1 and months 1, 2, 3, and 6) injection of the transduced hMSCs; the left ventricle ejection fraction (LVEF) was calculated as previously described. 18 All measurements were conducted in a blinded fashion to ensure impartial interpretation.
Preparation of Single-Cell Suspension From Hearts and Cell Staining for FACS Analysis
Three mice in each group were euthanized 2 weeks after hMSC/ medium injection. The hearts were collected, and single-cell suspensions were obtained by collagenase II ( 
Immunohistochemistry
Freshly excised tissues were immersed in optimal cutting temperature (OCT), frozen in liquid nitrogen, and stored at Ϫ80°C until use. OCT-embedded mouse hearts were sectioned to 5 m, collected on slides, and frozen at Ϫ80°C until staining.
For GFP and CD31 protein staining, heart sections were fixed with 3.7% paraformaldehyde (pH 7.4) at 4°C for 5 minutes immediately before staining, rinsed in PBS 3 times, and blocked at room temperature for 30 minutes in PBS containing 5% horse serum. Sections were then incubated with primary antibodies anti-CD31 (Abcam; San Francisco, CA) or anti-GFP (Clontech; Mountain View, CA) at room temperature for 1 hour. The sections were rinsed 3 times and incubated with the secondary antibodies (Alexa Fluor 488 -conjugated goat antimouse IgG and Alexa Fluor 568 rabbit antirat, Invitrogen; Carlsbad) at room temperature for 45 minutes. Paired primary and secondary antibodies were used for double staining. The slides were rinsed in PBS 3 times before adding mounting medium containing 4=,6-diamidino-2-phenylindole (17-DAPI) (Vector Labs; Burlingame, CA). FM was used to quantify vessel density by counting and averaging the number of vessels per field, based on 6 fields (ϫ400 magnified) randomly chosen from the border zone of each heart section.
For measurement of cardiac fibrosis, we chose 16 sections at 350-m intervals spanning the entire length of the heart from a total of 1100 sections 19 for the Masson trichrome approach, as previously described. 20 The cardiac fibrosis area (mm 2 ) in each section was obtained by staining and scanning the stained areas at ϫ10 magnification and quantifying ImageJ (National Institutes of Health). The areas of perivascular fibrosis in arteries and veins were excluded from the measurements. The total fibrotic volume (mm 3 ) in each heart was calculated from the sum of areas of fibrosis (A1ϩA2ϩ…ϩA16), multiplied by 0.35.
Statistics
We used the SPSS Smart Viewer 15.0 (SPSS; Chicago, IL) for statistical analysis of the data. A repeated-measures ANOVA was used for comparison of LVEF between the control and hMSC groups. Continuous data were analyzed by Mann-Whitney test between 2 groups or by 1-way ANOVA test with Bonferroni post hoc analysis for Ͼ2 groups. All data collection and analyses were performed in a blinded fashion.
Results
Validation of Constitutive and Endothelial-Specific Dual Reporter Lentivector
By using FM and FACS analysis, we determined that the average transduction efficiency of the U3/Tie-2-containing lentivector was 93.4Ϯ5.8% for mETCs ( Figure 1B and 1D ) and 94Ϯ6.3% for hMSCs ( Figure 1C and 1E) , respectively. More important, FM, FACS analysis, and in vitro BLI demonstrated that mETCs expressed both constitutive r-Luc and endothelialspecific f-Luc, whereas hMSCs expressed only r-Luc ( Figure  1F ). A robust linear correlation was observed between the number of transduced hMSCs and photon flux ( Figure 1G ), which allowed us to precisely quantify the BLI in vivo measurements.
Persistence and Differentiation of hMSCs After EMI
The transduced hMSCs were injected into the peri-infarct regions of SCID mice after EMI, as previously described. 21, 22 As shown in Figure 2A , all BLI signals are located in the chest, indicating that injected hMSCs did not migrate to peripheral organs in sufficient numbers to be detected. The endothelial-specific BLI/f-Luc signal was detectable at day 2 ( Figure 2A , bottom row, and 2B). Furthermore, both constitutive BLI/r-Luc and BLI/f-Luc signals declined gradually 1 week after injection and disappeared completely at day 60. These observations suggested that most hMSCs did not survive in the recipient hearts for Ͼ2 months, whether differentiated or not. By using immunofluorescent microscopy, we observed that GFP ϩ /CD31 ϩ cells, which represented differentiated hMSCs, resided in the border zone of infarcted hearts and that some of these cells were juxtaposed to endogenous endothelial cells ( Figure 2C and 2D) . FACS illustrated an increase in HLA-ABC ϩ /VE-cadherin ϩ cells, which represented hMSC-derived endothelial cells in hearts after hMSC injection, compared with medium injection (1.2% versus 0.1%; Figure 2E ). In each group, 6 mice were tracked with bioluminescence imaging (BLI) to monitor in vivo homing, distribution, and survival duration of injected hMSCs over 2 months; 6 mice were euthanized at 2 weeks after injection and then hearts were collected. Among the latter, 3 hearts were divided into sections for immunohistochemical staining with CD31 and GFP; the other 3 hearts were enzymatically digested to obtain a single-cell suspension for fluorescence-activated cell sorter (FACS) analysis. A, The BLI signals in the heart of a representative mouse were superimposed on photographs of a representative SCID mouse for the indicated time point after injection of hMSCs/medium after AMI. The signals were probed by intraperitoneal injection of coelenterazine (CLTZ) (top) or of D-Luc (bottom). B, Quantitative BLI intensity in SCID mice after hMSC/medium injection. BLI intensity was assessed by measuring the photon flux from the region of interest (ROI) drawn over the precordium. A repeated-measures ANOVA was used for comparison of the hMSC injection group with the control group at different time points (nϭ6 mice per group, *PϽ0.05 and **PϽ0.01). C, Immunostaining for CD31 and GFP showed the presence of endothelial differentiated hMSCs (GFP ϩ ) in the vessels of the border zone at 2 weeks after hMSC injection. Scale bar, 200 m. D, Higher magnification of the selection (dotted white square) shown in C. Immunostaining of CD31 (red) was performed to detect endothelial cells, and GPF was used to detect the endothelial differentiated hMSCs. Scale bars, 50 m (nϭ3 mice per group). E, Representative flow cytometry profile of cells isolated from the heart at 2 weeks after hMSC injection. The fluorescence intensity of cells stained simultaneously with antihuman HLA-ABC and either anticardiac troponin T (to detect cardiomyocytes) or anti-VE-cadherin (to detect endothelial cells) is shown. The percentage of VE-cadherin-positive cells was 10-fold higher in hMSC-injected mice than that in control mice (nϭ3 mice per group).
Improvement in Cardiac Function in the Infarcted Hearts After hMSC Injection
We used cardiac MRI to evaluate the therapeutic benefit of hMSC injection (Figure 3 ). End-systolic and end-diastolic volumes, measured longitudinally for up to 6 months, were used to calculate LVEFs ( Figure 3A) . One week after EMI, the decreases in LVEFs were similar in both the control and hMSC-injected groups ( Figure 3B ), suggesting that our EMI protocol was performed consistently and achieved a similar degree of cardiac damage in both groups. However, there was a statistically significant improvement in LVEFs in the hMSC-treated group compared with the control group, beginning at 1 month after EMI ( Figure 3B ). The improvement in LVEFs in the hMSC-treated animals was sustained for up to 6 months ( Figure 3A and 3B) . Overall, hMSC therapy produced a 10% net improvement in LVEF (PϽ0.05). No animals died in the 2 groups during the 6-month observation period.
Structural Changes After hMSC Injection
Although implanted hMSCs were detected in the hearts for Ͻ2 months, the improvement in cardiac function lasted for up to 6 months. To examine the mechanisms that may account for this long-term functional improvement, we measured the number of CD31 ϩ vessels in the border zone and quantified the fibrotic volume of the hearts at 2 weeks and at 6 months after hMSC treatment. As shown in Figure 4A and 4B, the overall number of CD31 ϩ vessels was significantly greater in the hMSC-treated hearts than in the control hearts (PϽ0.05). Moreover, there was a significant increase in vessel density in hMSC-injected hearts that was associated with this overall increase in total vessel number at both 2 weeks (83 versus 94 per field; PϽ0.05) and 6 months (69 versus 113 per field; PϽ0.01). Likewise, cardiac fibrosis was significantly diminished in the hMSCtreated hearts compared with the controls ( Figure 4C and 4D: 3.41 versus 2.09 mm 3 per heart; PϽ0.05), although at 2 weeks after injection, the degree of cardiac fibrosis was not different between these 2 groups. These results suggest that enhanced endogenous angiogenesis and attenuated fibrosis may be responsible for long-term improvement in cardiac function after hMSC therapy.
Discussion
Long-Term Survival, Efficacy of MSC Therapy, and Underlying Mechanisms
MSC treatment has been significantly protective against MI-associated heart damage by decreasing infarct size and reducing ventricular remodeling in short-term (Ͻ2 months) studies in a variety of animal models. However, the long-term (Ն6 months) effects have not been rigorously investigated and the outcomes from limited reports are not consistent. 23, 24 In the present study, intramyocardial delivery of hMSCs into the peri-infarct zones of SCID mouse hearts resulted in long-term (6 months) therapeutic benefits, as demonstrated by improvement in LVEF, a decrease in fibrosis, and an increase in vessel density in infarcted hearts. Teratoma formation in the hMSC-treated animals was not observed during the 6-month monitoring period, suggesting that this therapeutic strategy is potentially safe.
In our hands, hMSCs survived in the infarcted hearts for Ͻ50 days. Thus, the long-term therapeutic benefits cannot be directly ascribed to the short-term persistence of the injected hMSCs.
The longevity of MSCs is not consistent from study to study. Dai et al reported that, in a rat acute MI model, cardiac functional improvement was observed at 4 weeks after MSC transplantation. At 6 months, the therapeutic benefits were lost, although the injected cells were still observed in all tested time points. 23 By using a swine acute MI model, Jameel et al demonstrated that treatment with a bone marrow-derived multipotent progenitor cell population, a major proportion of which are MSCs, resulted in improvement in LVEF as early as 10 days after MI, and persisted to 4 months without significant multipotent progenitor cell engraftment. 18 , and continuing over a 6-month (M) period after injection. The meanϮSE was calculated for each group, and a repeated-measures ANOVA was used for comparison of LVEFs between control and hMSC groups (nϭ6 mice per group). NS, not significant. *PϽ0.05 and **PϽ0.01. Beginning at 1 month after hMSC injection, there was a significant difference in LVEF between groups at each time point.
In a human heart transplantation study, the MSCs of donor origin remained present in the heart for 6 years after transplantation and maintained cardiomyogenic and osteogenic differentiation capacity. 24 In a separate clinical study, van der Bogt et al compared the in vivo behavior of both adipose-and bone marrow-derived MSCs in the infarcted hearts and found that neither of these cell types restored cardiac function. 25 The differences in cell source, species, and experimental or clinical protocol and the potential differences in the disease model prevent direct comparison among the various investigations. 10, 12, 26 In this study, we used in vivo BLI to ascertain the viability of the injected hMSCs and cardiac MRI to assess LVEF. Compared with other imaging modalities, BLI is more sensitive and specific and can be performed in small live animals (eg, mice). 27 This approach allowed us to collect longitudinal in vivo imaging data, thereby avoiding sampling biases that can occur with the use of multiple animals euthanized at different time points for conventional histological staining. Moreover, the signal intensity is dynamically correlated with the original number of injected hMSCs and can be used to track engraftment and proliferation of transplanted cells. However, bioluminescence signals do not automatically equate to cell survival because of detection limits. By using BLI, investigators in several laboratories have accurately tracked the fate of injected human CD34 ϩ cells and adipose-and bone marrow-derived MSCs in the mouse heart after EMI. 18, 25 By using the same strategy, we demonstrated that bioluminescent detection of the injected hMSCs began to dissipate 1 week after injection and could not be detected beyond 50 days. Furthermore, by using immunofluorescent microscopy, we determined that MSCs differentiated into endothelial cells and integrated into the wall of blood vessels.
The therapeutic benefits of hMSC implantation cannot be directly attributed to the endothelial differentiation of hMSCs because a small subset of the cells undergoes differentiation. Therefore, the observed therapeutic benefits, manifested in increased vessel density and reduced fibrosis, are more likely to be attributed to paracrine effects exerted by factors released by hMSCs. 28 Numerous studies support the paracrinemediated therapeutic effects of MSCs on damaged myocardium through the secretion of protective factors that promote angiogenesis and attenuate fibrosis. Conditioned media from hypoxia-exposed Akt-expressing MSCs have protected rat cardiomyocytes grown under hypoxia and reduced infarct size in a rodent model. 29 Moreover, MSCs secrete angiogenic factors, such as vascular endothelial growth factor, basic fibroblast growth factor, and hepatocyte growth factor (HGF), that promote neovascularization, 30, 31 and downregulation of vascular endothelial growth factor expression in MSCs has reduced myocardial recovery. 32 MSC transplantation into ischemic rat myocardium has also reduced fibrosis and increased myocardial thickness, improving cardiac function without concomitant myocardial regeneration. 33 MSCs can downregulate extracellular tissue remodeling in a paracrine manner by inducing myocardial expression of collagens I and III and tissue inhibitor of metalloproteinase-1 and by decreasing matrix metalloprotease 2 and 9 expression levels. 34 The paracrine therapeutic effect can also be manifested in the induction of endogenous cardiac progenitor cell differentiation via MSC-secreted bone morphogenetic protein (BMPs) and fibroblast growth factor, modulators of cardiac cell differentiation. 35 ϩ vessels in 6 fields (ϫ400) was counted and averaged. D, Morphometric analysis of cardiac fibrosis was performed as described in the Methods section and elsewhere. 19 The meanϮSE was calculated for each group, and the Student t test was used to evaluate the differences between the groups (nϭ3 mice per group). *PϽ0.05 and **PϽ0.01.
In Vivo Detection of hMSC Differentiation Into Endothelial Cells in the Infarcted Myocardium
There is accumulating evidence that MSCs can differentiate into cardiac endothelial and smooth muscle cells under a variety of in vitro conditions. 10, 12, 26, 36, 37 However, confirmation of such in vivo conditions has been hampered by the limited availability of noninvasive modalities. In this study, we created a lentiviral reporter with 2 sets of DFR genes, C/r-Luc, controlled by the constitutive promoter murine stem cell virus, and G/f-Luc, driven by the endothelial-specific promoter Tie-2. We showed that there is robust constitutive C/r-Luc expression in both hMSCs and mETCs in vitro. As expected, G/f-Luc expression was only observed in mETCs. Consistent with the in vitro observation, undifferentiated hMSCs, when injected into the infarcted hearts, underwent endothelial differentiation, as demonstrated by robust f-Luc expression in the injected areas. We validated our bioluminescent results using immunohistochemistry (IFM). More important, by using CD31 staining and cardiac MRI, we found that endothelial differentiation correlated with the formation of blood vessels in the peri-infarct zones and an improvement in LVEF, respectively. The endothelial inducible BLI signal reached a maximum 1 week after injection and disappeared with the constitutive BLI signal at day 50. The concurrent regression of both tissue-specific and constitutive BLI signals implies a decline in implanted cell population survival.
MSCs and Cardiac Repair
Growing evidence suggests that the therapeutic benefit of MSCs appears to be mediated predominantly via paracrinemediated effects, rather than direct regeneration of various cardiac cells by differentiation. 12,27,31,38 -42 In this study, we found that injected hMSCs differentiated into endothelial cells during the early stages (1-2 weeks after injection), as determined by the presence of HLA-ABC ϩ /CD31 ϩ cells that reside in the peri-infarct regions. A few of them even integrated into the wall of newly formed vessels. In agreement with other reports, our finding suggests that at an early stage after transplantation, hMSCs may play a role in creating new vessels. Thus, our findings support the notion that abolishing MSC-derived angiogenesis at the early stage may adversely affect the repair process. 43 We observed that only a few HLA-ABC ϩ /CD31 ϩ cells were detected in the injected heart sections and that the differentiated endothelial cells survived in the damaged heart for Ͻ50 days. Conversely, the increase in vessel density and the decrease in fibrosis persisted up to 6 months and paralleled long-term functional improvement. Thus, it is more likely that the injected hMSCs trigger endogenous repair mechanisms. These may include release of various paracrine factors and cytokines that may prevent the adverse inflammation caused by cardiac infarction and stimulation of repair processes.
